BIOC Stock - Biocept, Inc.
Unlock GoAI Insights for BIOC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $25.86M | $61.25M | $27.46M | $5.53M | $3.25M |
| Gross Profit | $-2,582,000 | $23.48M | $6.12M | $-5,448,954 | $-6,801,437 |
| Gross Margin | -10.0% | 38.3% | 22.3% | -98.6% | -209.3% |
| Operating Income | $-31,983,000 | $-2,409,000 | $-15,468,255 | $-23,056,939 | $-24,258,739 |
| Net Income | $-32,087,000 | $-2,824,000 | $-17,042,320 | $-24,614,709 | $-24,571,601 |
| Net Margin | -124.1% | -4.6% | -62.1% | -445.2% | -756.0% |
| EPS | $-56.78 | $-5.73 | $-43.16 | $-357.54 | $-2634.46 |
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
Visit WebsiteEarnings History & Surprises
BIOCEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Aug 12, 2024 | — | — | — | — |
Q2 2024 | May 8, 2024 | — | — | — | — |
Q4 2023 | Nov 20, 2023 | — | $-9.91 | — | — |
Q3 2023 | Aug 14, 2023 | — | $-3.50 | — | — |
Q2 2023 | Apr 17, 2023 | — | $-32.73 | — | — |
Q1 2023 | Mar 29, 2023 | $-0.22 | $-32.57 | -14702.3% | ✗ MISS |
Q4 2022 | Nov 21, 2022 | $-4.80 | $-9.91 | -106.5% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.16 | $-9.31 | -5718.8% | ✗ MISS |
Q2 2022 | May 23, 2022 | $-7.21 | $-4.80 | +33.4% | ✓ BEAT |
Q2 2022 | Apr 6, 2022 | — | $-5.41 | — | — |
Q4 2021 | Nov 15, 2021 | $2.70 | $0.90 | -66.7% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | $-0.16 | $-4.20 | -2525.0% | ✗ MISS |
Q2 2021 | May 12, 2021 | — | $5.71 | — | — |
Q1 2021 | Mar 29, 2021 | — | $4.20 | — | — |
Q4 2020 | Nov 12, 2020 | $-14.41 | $-12.91 | +10.4% | ✓ BEAT |
Q3 2020 | Aug 12, 2020 | $-12.01 | $-15.02 | -25.1% | ✗ MISS |
Q2 2020 | May 13, 2020 | — | $-24.02 | — | — |
Q1 2020 | Mar 25, 2020 | $-1.00 | $-60.06 | -5906.0% | ✗ MISS |
Q4 2019 | Nov 13, 2019 | $-2.70 | $-75.08 | -2680.7% | ✗ MISS |
Q3 2019 | Aug 12, 2019 | $-1.90 | $-114.11 | -5905.8% | ✗ MISS |
Latest News
Frequently Asked Questions about BIOC
What is BIOC's current stock price?
What is the analyst price target for BIOC?
What sector is Biocept, Inc. in?
What is BIOC's market cap?
Does BIOC pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BIOC for comparison